Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been
associated with increased risk of relapse and death in patients with acute myeloid leukemia …

Technological advances in the laboratory have led to substantial improvements in clinical
decision making through the introduction of pretreatment prognostic risk stratification factors …

Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in
hematologic complete remission after multiagent therapy exhibit minimal residual disease …

Purpose Patients with acute myeloid leukemia (AML) who are in morphologic complete
remission are typically considered separately from patients with active disease (ie,≥ 5 …

Importance Tests that predict outcomes for patients with acute myeloid leukemia (AML) are
imprecise, especially for those with intermediate risk AML. Objectives To determine whether …

Purpose This study assessed the prognostic impact of postinduction NPM1-mutated (NPM1
m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute …

Although the majority of patients with acute myeloid leukemia (AML) initially respond to
chemotherapy, many of them subsequently relapse, and the mechanistic basis for AML …

Purpose Older patients with acute myeloid leukemia (AML) have a high relapse rate after
standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by …

Minimal residual disease (MRD) is associated with adverse outcome in acute myeloid
leukemia (AML) after myeloablative (MA) hematopoietic cell transplantation (HCT). We …

Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1)
pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual …